Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas Jahanmohan JudithJean-Christophe EymardMélanie PougetFabrice KwiatkowskiIsabelle Van PraaghLaurent SavareuxMarc AtgerXavier DurandoCatherine AbrialDamien RichardAngeline GinzacEmilie ThivatBrigitte MonangePhilippe CholletHakim MahammediPublished in: Cancer medicine (2021)
Even though our previous studies and data in the literature seemed to support an association between curcumin and cancer therapies in order to improve patient outcome and prognosis, the results from this interim analysis clearly showed that adding curcumin to mCRPC patients' treatment strategies was not efficacious. The study was discontinued on the grounds of futility.
Keyphrases
- phase ii study
- double blind
- open label
- locally advanced
- placebo controlled
- end stage renal disease
- squamous cell carcinoma
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- papillary thyroid
- systematic review
- prognostic factors
- case report
- phase ii
- clinical trial
- rectal cancer
- radiation therapy
- peritoneal dialysis
- machine learning
- study protocol
- young adults
- cross sectional
- lymph node metastasis
- data analysis
- patient reported